News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-10-16 pm EDT			5-day change	1st Jan Change
37.00 ^USD	-2.17%		-0.19%	+20.13%

Oct. 16	Nordic stocks in North America - Ericsson rose 2.6 percent	FW
Oct. 15	Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug	RE

All News

Mentions Relevance

Oct. 14	UBS Raises Genmab Price Target to DKK 3,100 (2,700), Reiterates Buy	FW
Oct. 13	Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2026	CI
Oct. 13	Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J	MT
Oct. 13	Genmab: Darzalex sales reached $4.2bn in third quarter	FW
Oct. 13	Genmab reports Darzalex sales of $4.24bn	FW
Oct. 13	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026	GL
Oct. 13	BNP Paribas raises its price target for Genmab to DKK 2,850 (2,600), reiterates outperform - BN	FW
Oct. 09	BofA 'Bullish' on Genmab's Upcoming Phase 3 Readouts; Buy Rating Maintained	MT
Oct. 09	Deutsche Bank raises price target for Genmab to 3,000 Danish kroner, reiterates buy	FW
Oct. 09	Deutsche Bank raises price target for Genmab to DKK 3,000 (2,750), reiterates buy	FW
Oct. 08	Barclays raises price target for Genmab to DKK 3,100 (2,900), reiterates overweight	FW
Oct. 07	Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members	GL
Oct. 07	Genmab: Beyond Darzalex
Oct. 07	Deutsche Bank Research Raises Genmab PT, Keeps Buy Rating	MT
Oct. 07	Deutsche Bank reiterates buy on Genmab, raises price target to DKK 2,750	FW
Oct. 07	DNB Carnegie raises price target for Genmab to DKK 2,850 (2,300), reiterates buy	FW
Oct. 06	Bank of America raises target price for Genmab to 2,850 Danish kroner (2,500), reiterates buy	FW
Oct. 06	Deutsche Bank raises price target for Genmab to DKK 2,750 (2,500), reiterates buy	FW
Oct. 06	Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug	DJ
Oct. 06	Jefferies impressed by Genmab's results in a phase 3 study
Oct. 06	SEB reiterates Buy on Genmab, raises price target to DKK 3,000 (Update)	FW
Oct. 06	SEB raises its price target for Genmab to DKK 3,000 (2,600), reiterates buy	FW
Oct. 06	Barclays: Genmab's Epkinly beats expectations	FW
Oct. 05	Genmab, AbbVie Report Positive Results from Phase 3 Trial of Diffuse Large B-Cell Lymphoma Treatment	MT
Oct. 05	Genmab A/S And AbbVie Announce Epcoritamab In Combination With R-CHOP Demonstrates Statistically Significant Improvement In Progression-Free Survival In Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI